Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsA trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care
1.
Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer
2.
Hospitalized Kate Middleton; Sen. Paul Demands That Fauci Go To Prison; COVID Returns to Class.
3.
Loneliness and social isolation linked to heightened risk of death in those with cancer
4.
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer
5.
The Cherenkov color image shows the possibility of improving the quality of radiation therapy.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
3.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
4.
The Latest Research on Acute Promyelocytic Leukemia: Advancements in Diagnosis and Therapy
5.
Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge